Use of the 40-Gene Expression Profile (40-GEP) Test in Medicare-Eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs . J of Skin [Internet]. 2024 Jan. 16 [cited 2025 Apr. 17];8(1):s336. Available from: https://skin.dermsquared.com/skin/article/view/2460